Canadian firm BenchSci has secured around $50 million in third-round financing that will be used to speed up the adoption of its artificial intelligence-powered platform for biomedical rese
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.